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ducted using patient costs from billing records, and three differ-
ent effectiveness measures [all based on a 0 (worst) to 100 (best)
scale]. The primary CE analysis used Subject General Well Being
score (SGWB), which was a general health assessment question.
Two other effectiveness measures were β-mediated treatment
effect (BMTE) and Disease Symptom Assessment (DSA) scores.
RESULTS: LEV patients required fewer total nebulizations
(median 10 vs 12; p = 0.031), and the two groups were not sta-
tistically different with respect to the number of rescue nebu-
lizations, length of hospital stay, and total hospital cost. For the
primary CE analysis, LEV was as effective (70.0 vs 68.3) and
cost $164 less per patient compared with RAC. For CE analy-
ses using BMTE and DSA, LEV was again as effective (86.9 vs
79.0 and 59.2 vs 57.2, respectively) and cost $174 less per
patient. Bootstrap re-sampling analyses found that approxi-
mately 65%–77% of the 10,000 simulations for LEV fell within
the dominant quadrant on a CE plane. CONCLUSION: In this
study, LEV patients required signiﬁcantly fewer total nebuliza-
tions without an increased need for rescue nebulizations. CE
analysis indicated that LEV was at least as effective as RAC with
a $164 savings in costs.
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OBJECTIVES: This was a prospective, randomized, multicenter,
open label study to determine the cost-effectiveness (CE) of lev-
albuterol versus racemic albuterol in patients hospitalized for
acute asthma or COPD; here we present a subset CE analysis
which focuses on quality-adjusted length of stay (QLOS) as a
measure of effectiveness. METHODS: Patients were randomized
to either levalbuterol (n = 241) or racemic albuterol (n = 238).
We conducted an exploratory CE analysis using QLOS, which
was developed to reﬂect the relative rapidity of symptom reso-
lution over the patient’s hospital stay, conceptually similar to Q-
TWiST. A measure of overall HRQoL based on daily responses
to the Subject General Well-Being (SGWB) score was used as the
utility value. An overall value was obtained by calculating the
sum over the time period, resulting in the QLOS score. QLOS
was also calculated for two other effectiveness measures, Disease
Symptom Assessment (DSA) and beta-mediated treatment effects
(BMTE). Hospital charges obtained from billing records 
were converted to costs by applying cost-to-charge ratios. A
cost/QLOS comparison was made between treatment groups.
Sensitivity analyses examined different time periods and mea-
sures of effectiveness. Bootstrap sampling was used to generate
10,000 samples for each analysis. RESULTS: When SGWB was
the effectiveness measure, levalbuterol compared to racemic
albuterol was associated with lower costs ($3676 vs. $3841,
respectively) and slightly better cumulative effectiveness (11.99
vs. 12.68, respectively; lower value better health). Similar results
were observed using other time periods and BMTE as the effec-
tiveness measure. Results from bootstrap sampling showed that,
in the majority of samples, levalbuterol was associated with
better health and lower costs than racemic albuterol. When DSA
was used, racemic albuterol was slightly more effective but more
costly than levalbuterol. CONCLUSION: In this study using
prospectively collected cost data and QLOS scores, levalbuterol
was at least as effective as racemic albuterol, with total costs that
were $165 less.
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OBJECTIVES: To examine health outcomes and costs for
patients with severe and non-severe asthma in a managed care
setting over a 4-year period. METHODS: An administrative
claims database (8.8 million lives) was analyzed (June 2000–May
2004). Patients aged ≥12 years with an ICD-9 code for asthma
and ≥2 claims/year for asthma medication were included; those
with other signiﬁcant respiratory conditions were not. Patients
using omalizumab, continuous oral corticosteroids (OCS),
Advair 500/50, or high-dose inhaled corticosteroids in combi-
nation with any other asthma medication were considered 
to have severe asthma. Outcomes in years 2–4 for patients 
with severe asthma in year 1 were compared with those of
patients with non-severe asthma in year 1. Lack of control was
deﬁned as an asthma-related hospitalization or emergency
department (ED) visit, OCS burst for asthma, more than 4 clinic
visits for asthma per year or more than 2 per quarter, or more
than 5 prescriptions for asthma rescue medication per year.
RESULTS: Of 3998 patients identiﬁed (mean age = 41 years,
65% female), 594 (15%) had severe asthma in year 1. Patients
with severe asthma had signiﬁcantly more hospitalizations per
1000 patients per year (7.2 vs 4.3; p < 0.001), ED visits per 1000
patients per year (8.8 vs 6.1; p = 0.004), clinic visits for asthma
per patient per year (2.93 vs 1.98; p < 0.001), asthma costs per
patient per year ($1331 vs $817; p < 0.001), and lack of control
events per 1000 patients per year (547 vs 462; p < 0.001) than
patients with non-severe asthma. CONCLUSION: Patients with
severe asthma used signiﬁcantly more health care resources than
patients with non-severe asthma. In addition, a signiﬁcant
number of patients in both groups met the deﬁnition for lack of
control.
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OBJECTIVES: To examine patterns and economic outcomes of
allergy immunotherapy (IT) care among children with allergic
rhinitis (AR). METHODS: We examined the 1997–2004 Florida
Medicaid dataset to identify children (<18 years) who received
an AR diagnosis and IT. Those receiving IT who were continu-
ously enrolled and had data ≥4 years following and ≥1 year prior
to initial AR diagnosis were included in clinical and economic
subanalyses. RESULTS: There were 104,963 children diagnosed
with AR; 5532 (5.3%) received IT. Mean age at IT initiation was
8.2 years (SD 3.5). Compared to those with AR who did not
receive IT, children who received IT were signiﬁcantly older
(mean age 7.7 versus 7.0, SD 3.6, p = 0.001). Signiﬁcantly less
patients receiving IT were female or Caucasian (p ≤ 0.001). The
average number of IT administrations was 22 (SD 27.0); approx-
imately half of patients (45.2%) received less than 10 IT admin-
istrations. Average treatment duration was 1 year (SD 15.8
months); more than half (51.2%) of patients received IT for less
than 6 months, and only 1 in 12 patients (8.7%) completed the
